DSM acquires Pentapharm
This article was originally published in The Rose Sheet
Executive Summary
DSM Nutritional Products' acquisition of cosmetic active ingredient specialist Pentapharm further strengthens its No. 1 position as the global leading supplier of active ingredients for skin care and sun care, firm announces July 7. Headquartered in Basel, Switzerland, Pentapharm offers patent-protected cosmetic active ingredients such as Erythrulose for self-tanning, the anti-wrinkle synthetic tripeptide Syn-Ake, and Vialox, "a highly effective topical alternative to Botox," in addition to ingredients for body-slimming and whitening products. The acquisition "enriches our existing personal care portfolio of vitamins and sun-filters with highly specialized actives," DSM's Krijn Rietveld, senior VP and head of new business development, says. Personal care is a "key area" DSM plans to build upon by 2010, board member Stephan Tanda adds. Pentapharm, which commands annual revenues of approximately $54.5 mil., employs about 200 people at locations in Switzerland, Japan and Brazil. The parties have agreed not to disclose financial details...
You may also be interested in...
Anti-aging peptide from DSM
New peptide formula Syn-Glycan from Swiss supplier DSM Nutritional Products can be used as a bioactive ingredient in cosmetics to reduce visible signs of aging, boosting skin's production of hyaluronan in the dermis which "firms skin from the inside out." Product also increases levels of proteins decorin and lumican, which make collagen fibers thinner and stronger. Part of the appeal of Syn-Glycan is its versatility, says Dr. Goede Schueler, senior business development manager for skin care. The glycerin-based aqueous solution can be used in firming treatments, facial contour and remodeling creams, anti-sagging treatments, moisturizing lotions, anti-aging solutions and anti-cellulite gels, firm says. The 2007 acquisition of cosmetic ingredient specialist Pentapharm made personal care a "key area" of development for DSM (1"The Rose Sheet" July 9, 2007)
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.